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Abstract  
The aim of this paper is to describe the emerging role of the palliative care clinical trials 
nurse in an era of evidence based practice and increasing clinical trial activity in 
palliative care settings across Australia. An overview of the current clinical trials work is 
provided with a focus on three aspects of clinical trials nursing practice which have 
significant implications for patients: (1) the consent process; (2) integration of clinical 
trials into multidisciplinary care, and (3) promotion of evidence based practice in 
palliative care settings. Clinical trials roles provide palliative care nurses with an 
opportunity to contribute to clinical research, help expand palliative care’s evidence base 
as well as develop their own research capabilities.  
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Introduction 
Currently there is increasing research activity in palliative care settings in Australia and 
as a result new clinical research roles have been created. The aim of this paper is to 
describe the emerging role of the palliative care clinical trials nurse with a focus on:1) 
management of the consent process, 2) integration with multidisciplinary care, and 3) 
establishing and building the evidence base in the palliative care setting. 
Need to develop the evidence base 
In this era of evidence based practice there is a compelling need for processes which 
support rigorous enquiry and evidence generation. As part of Australia’s universal health 
care system, the Pharmaceutical Benefit Scheme (PBS) ensures that a range of 
medications are subsidised and available to all who need them. However, many 
medications commonly used for symptom management in the palliative care population 
lack the high level evidence required for PBS subsidisation, despite the use of various 
medications in a palliative care setting often being outside of the manufacturer’s 
recommendations. An example of this is the use of Octeotide in the treatment of 
malignant bowel obstruction: it is currently not approved for this indication despite 
widespread clinical use in the palliative care setting. The use of this medication outside of 
the PBS guidelines has significant cost implications for both inpatient settings and 
outpatients. 
The Palliative Care Clinical Studies Collaborative (PaCCSC) was established in 2006 
through funding from the Australian Government Department of Health and Ageing 
under the National Palliative Care Program to address this evidence gap. Twelve 
Australian palliative care services are now involved in a number of Phase III PaCCSC 
clinical medication trials as partner organisations (Table 1). The primary aim of PaCCSC 
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is to generate research data that will support the listing of these medicines on the 
Australian Register of Therapeutic Goods and subsequently on the PBS (Table 2), with 
secondary aims of building the research capacity and evidence base of the palliative care 
sector through Phase III and IV clinical medication studies. Currently there are six 
clinical trials underway with the Collaborative’s first clinical trial recently successfully 
completed recruitment (Hardy et al). More detailed information about PaCCSC and its 
current clinical trials can be found on the Caresearch website (at 
http://www.caresearch.com.au/caresearch/tabid/97/Default.aspx). 
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Table 1: Current Partner Organisations  
State Name of Organisation 
NSW Braeside Hospital, Sydney 
 Calvary Mater Newcastle, Newcastle 
 Calvary Health Care, Sydney 
 Sacred Heart Centre, Sydney 
Victoria Peter MacCallum Cancer Institute, Melbourne 
 Ballarat Hospital, Ballarat 
 St Vincent's Hospital, Melbourne 
 The Alfred Hospital, Melbourne 
 Austin Health, Melbourne 
 Barwon Health, Geelong 
Queensland Mater Health, Brisbane 
South Australia Southern Adelaide Palliative Services, Adelaide 
(See http://www.caresearch.com.au/caresearch/tabid/759/Default.aspx) 
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Table 2: Current Phase 3 Clinical Trials* 
Study Chief Investigator 
Ketamine for cancer pain Professor Janet Hardy 
Risperidone and Haloperidol for delirium Associate Professor Meera Agar 
Octreotide for vomiting related to  
malignant bowel obstruction 
Professor David Currow 
Morphine and Oxycodone for Dyspnoea 
Sertraline for dyspnoea 
Megastrol for appetite Dr Paul Glare 
*All are randomized, double-blinded, placebo controlled trials. 
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Challenges in Conducting Palliative Care Research  
The ethical and methodological considerations of conducting research within palliative 
care have been well documented (Aoun & Kristjanson, 2005). Despite randomised 
controlled trials (RCTs) providing high level evidence, it has been suggested that they are 
often inappropriate in palliative care settings because of the use of a placebo arm (Karim 
2000). In the past many palliative care RCT have lacked rigor and power due to high 
attrition rates, poor design and reporting or failure to adequately recruit (Hudson et al, 
2001; Piggott et al 2004; Manchikanti 2008). Given the vulnerability of the palliative care 
population, many potential trial participants may experience frailty, fatigue, fluctuations 
in condition and cognitive decline (Whiting & Vickers 2010). These conditions may 
impact on an individual’s decision making capacity and willingness to commit the time 
and energy research participation requires (Karim, 2000; Dean & McClement, 2002; 
Seymour et al, 2005; Whiting & Vickers 2010). Further, it is not uncommon for palliative 
care participants to deteriorate and die during the intervention or the follow up stages of a 
clinical trial, necessitating sensitive withdrawal and ongoing ethical and safe care of 
participants and their family. The complexity of these ethical and clinical issues may 
explain a reluctance of health professionals to refer patients for consideration of inclusion 
in palliative care studies and a reluctance of families to further burden the patient with 
this additional task. This well intentioned gate keeping has been frequently cited as a 
major barrier to participation in palliative care clinical trials (Dean & McClement 2002; 
White et al 2008; O’Mara et al 2009).   
Despite these significant challenges, collaborative clinical trials work is being conducted 
at across Australian at 12 palliative care centres with over 450 palliative care patients 
consenting to participate in these studies during since 2008. Given this level of research 
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activity is therefore timely to articulate the role of the palliative care clinical trials nurse 
and how it facilitates the recruitment and management of the care needs of participants.  
Discussion 
Developing the Role and Addressing the Learning Needs of the Palliative Care Clinical 
Trials Nurse 
At the outset, it was determined that the palliative care clinical trials nurses would be 
integral members of the research teams, the PaCCSC network and the multidisciplinary 
clinical team. Alongside the Site Investigator, the clinical trials nurse plays a pivotal role 
in linking the science within the protocols to the reality of complex clinical cultures and 
individual patient situations. The clinical trials nurse role is broad, with varying 
responsibilities depending on the site, jurisdiction and the capabilities of the individual 
nurse (Table 3). Learning needs of the clinical trials nurses include developing 
knowledge of recruitment and other clinical trial processes, research and ethics concepts, 
budgeting and financial reporting. Examples of education undertaken to meet these 
learning needs include International Conference on Harmonisation – Good Clinical 
Practice training (Therapeutic Goods Administration, 2000) and specific study initiation 
training prior to commencement of each study at each site. Being part of a larger 
collaborative such as PaCCSC ensures that each clinical trials nurse, although operating 
at distinct local sites across a vast country, has ready access to ongoing support, 
continuing professional development opportunities and a community of practice. The 
practical support provided by PACCSC ensures the development of required knowledge 
through the identification of learning needs, training workshops, regular teleconferences 
and quality assurance processes. This support has been critical to developing the 
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necessary capabilities to successfully recruit and patients, secure consent, implement the 
trials and integrate the clinical trial activities into multidisciplinary practice. 
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Table 3: Overview of the palliative care clinical trials nurse role* 
Role  Activities 
Coordination  Developing pro-active referral systems, eligibility screening, obtaining informed consent, obtaining study 
medication, administering study intervention, efficacy and safety assessments, cessation of intervention,+/- 
withdrawal, follow up period: symptom and safety assessments, adverse event reporting, data collection, entry 
and management, participation in monitoring activities 
Management of  
Ethical Submissions 
Submission of new protocols, submission of amendments to protocols, management of ethics documentation, 
ensuring compliance with protocols, ethics reporting: adverse events, progress reports 
 Integration with  
Multidisciplinary 
 Care 
 
Identification as a member of the multidisciplinary team (MDT), obtaining referrals from MDT and discussing 
with treating consultant, sharing information obtained from the participant (with their permission) with the 
MDT, accurate and timely documentation of study processes, referral of patient to other MDT members or 
services where required, use of palliative care nursing skills and knowledge to support patients and carers 
Promotion of  
evidence based practice and 
research 
 
Demonstrating ethical and effective study processes, identifying staff knowledge needs, planning and 
conducting education, sharing information about the progress of each trial with the MDT, highlighting 
evidence-practice gaps eg the use of off license medications, participating in MDT activities which promote 
evidence based practice, communicating and celebrating the research activities and achievements  
Management/Administration 
 
Managing study budgets and financial reporting, development of systems, processes and resources, 
recruitment, orientation and coordination of study staff 
*Aspects of the role are delegated by the Site Investigator, who accepts overall responsibility for the conduct of the trials and the medical care of 
participants. Many aspects of the role are completed in collaboration with the Site Investigator, eg adverse event reporting.
11 
 
Archived at Flinders University: dspace.flinders.edu.au
The consent process 
At the majority of sites, the clinical trials nurse is responsible for actively seeking 
referrals and obtaining patient consent. The national ethics applications for each clinical 
trial specified that the clinical trials nurse could obtain consent from participants with the 
supervision of and delegation by the Site Investigator. Prior to study commencement the 
clinical trials nurses and investigators are trained in consent procedures for this study, 
with the opportunity to role play scenarios and develop a consent script to ensure all 
information is fully covered. Obtaining consent is therefore part of the role of the clinical 
trials nurse, subject to the requirements of local institutional ethics committees, which 
may varies from usual clinical trials practice in many jusidictions where consent is 
usually by a medical practitioner. 
Throughout the consent process the clinical trials nurse applies knowledge of ethical 
research principles and regulations around consent to individual situations, with a 
dynamic counterpoise between the philosophies of beneficence, nonmaleficence and 
respect for individual autonomy (Hopkinson et al 2005; National Health and Research 
Council, Australian Research Council & Australian Vice-Chancellors' Committee, 2007; 
White et al 2008). The clinical trials nurse gives information about the study and assesses 
the impact of symptoms, illness and individual characteristics on the patient’s capacity to 
receive and understand the information.  
There are often marked variances between patients’ capacity to make decisions and 
willingness to participate in clinical trials. In the interactions with Mr D (Case Study 1) 
and Mr R (Case Study 2) the clinical trials nurse assessed their capacity, eligibility and 
willingness to consider the Ketamine study and responded appropriately to each (Refer 
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Table 4).  Care was taken to honestly and sensitively explain that symptoms may not be 
relieved during the study, recognising that for many patients hope of relief plays a part in 
their decision to participate in clinical trials. In Mr D’s case, he was both willing and 
eligible to participate, and had the capacity to give consent, whilst it became evident 
during the pre-consent process that Mr R may not be either eligible or capable of giving 
an informed consent. As Mr R indicated he did not want to participate, confirmation of 
his capacity was not sought. These case studies illustrate the complexity of the 
interactions between the clinical trials nurse and each patient during the consent process, 
and the need for ethical, transparent and clinically skilled interactions. 
Transparency around the consent process is achieved through optimal communication, 
both verbal and written, with the patient, their family and the multidisciplinary team: all 
interactions between the clinical trials nurse and the patient are documented in the 
patient’s medical record, and a copy of the written consent form placed in the clinical 
file. Through these means the nurse models ethical research practice in the consent 
process, ensures it is open to scrutiny, ensures that the multi-disciplinary team is kept 
informed of the process and promotes the continuance of referrals (White et al 2008; 
Whiting & Vickers 2010). 
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Table 4: Case Studies Mr D and Mr R – Obtaining informed consent 
Stages in consent 
process 
Case study – Mr D Case Study - Mr R 
Referral  Mr D, an 81 year gentleman with metastatic lung cancer 
with poorly managed pain, AKPS 60. He was referred for 
consideration for inclusion in the Ketamine study (Hardy et 
al) by the medical registrar. 
Mr R, a 76 year old gentleman with metastatic colorectal 
cancer, AKPS 50 was referred for consideration in the 
Ketamine study (Hardy et al) by the medical registrar. 
Physician 
confirmation 
The treating Physician was aware of the referral and happy 
for the patient to be approached about the study. 
The treating Physician was aware of the referral and happy 
for the patient to be approached about the study. 
Approaching the 
patient 
The clinical trials nurse approached Mr D introduced 
herself and her role. Mr D was alert, and willing to discuss 
the study. The clinical trials nurse spent approximately 15 
minutes with Mr D getting to know his circumstances. 
The clinical trials nurse approached Mr R introduced 
herself and her role. Mr R was alert but appeared 
dishevelled. He agreed to discuss the study. The clinical 
trials nurse spent time with Mr R getting to know his 
circumstances, but quickly noticed that Mr R was 
distractible and fidgety. 
Assessing the 
symptom 
Mr D gave a clear description of the location, quality and 
intensity of his pain, and gave a numerical rating score 
(NRS) of 5/10 on average over the previous 24 hours. Mr 
D’s level of pain meant that in relation to the symptom 
under investigation he was eligible to participate. 
Mr R stated that he had pain in his back, but he was not 
able to give a NRS. Due to Mr R’s difficulty scoring his 
pain it was not yet clear if he was eligible to participate in 
the study. 
 
Checking it is OK to 
continue 
Mr D stated he wanted to hear about the study. The nurse asked Mr R if he wanted anything for pain. Mr 
R stated he did not want anything for pain at that time and 
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he was willing to hear more about the study. 
Explaining the study 
in detail 
The nurse explained the purpose, duration and type of 
intervention, the assessments required, and what was meant 
by a placebo controlled trial and what implications this 
would have for his pain management.  Mr D was informed 
that the study was voluntary and his personal details would 
be confidential. Mr D was offered the written information 
sheet. 
The nurse started explaining the study in more detail to Mr 
R, but before all the information was given Mr R made a 
statement about participation. 
Gauging the patient’s 
response 
Mr D took the written information sheet, and requested that 
the nurse speak with his wife, son and GP about the study. 
Mr R said: “Yes, yes, I’ll do it, anything so as get rid of 
this pain”. The nurse explained that participation would 
not guarantee that pain would be relieved, and again 
outlined the placebo-controlled nature of the study. Mr R 
said “Oh, no, then I don’t want the study, I want to just 
have the medication”. 
Assessing capacity The nurse assessed Mr D’s capacity to understand the 
implications of the study throughout their discussion. Her 
assessment was that Mr D understood the information and 
was able to give informed consent. A Mini-Mental 
assessment was completed to confirm capacity to consent: 
Mr D scored 27/30. 
The nurse assessed Mr R’s capacity to understand the 
implications of the study throughout their discussion. Her 
assessment was that Mr R was having difficulty 
understanding the implications of participation, and may 
not have the capacity to give an informed consent. A Mini-
Mental assessment was not completed as Mr R declined 
participation.  
Communicating Mr D was thanked for agreeing to participate in the study, The clinical trials nurse acknowledged the impact of the 
15 
 
Archived at Flinders University: dspace.flinders.edu.au
acceptance of the 
patient’s decision 
and given information about the assessments that were 
required to confirm his eligibility. Once eligibility was 
confirmed Mr D was informed when the study intervention 
would start. 
pain on Mr R, advised him that she would inform his 
medical team about his decision, and thanked him for 
taking the time to consider the study.  
Obtaining written 
consent 
Mr D signed the consent form, and a copy was given to 
him, and another copy placed in the clinical file. 
Written consent was not sought from Mr R. 
Communicating with 
the team and 
documenting the 
consent process 
The nurse informed the site investigator and the medical 
and nursing team of Mr D’s consent to participate. All 
aspects of their discussion were documented in the clinical 
file. 
The discussion was documented by the nurse in the 
clinical file, and the medical and nursing team informed of 
his response, current pain and cognitive symptoms.  
Outcome Mr D commenced the Ketamine study the next day. He 
withdrew on Day 3 because he was experiencing side 
effects that were not acceptable to him. The nurse 
completed weekly follow up visits for 3 weeks During this 
time Mr D’s condition deteriorated and he died less than 
four weeks after participation. 
Overnight Mr R became more unwell, developing a chest 
infection and delirium. He continued to deteriorate and 
died 18 days later.   
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Integration with multidisciplinary care 
Specialist palliative care is generally delivered by multidisciplinary teams (MDT) who 
are configured to address the unique needs of each patient and their families (Palliative 
Care Service Provision in Australia: A Planning Guide, 2006, p.8). These teams work 
within the World Health Organisation (2003) definition of palliative care, which 
emphasises impeccable assessment, relief of symptoms and distress, holism, quality of 
life and acceptance of dying as a normal process. These principles and the advanced 
illness and complexity of needs for many palliative care patients demand that the clinical 
trial nurses develop strategies to meet the needs of participants, their families, the MDT 
and the study and that there is sound integration between each element.  
 Communication 
With the Site Investigator, the clinical trials nurse is responsible for communicating the 
purpose, rationale, protocols and progress of each study to the MDT members. 
Developing communication and a collaborative relationship with members of the MDT is 
critical to integrating clinical trials as another element of usual palliative care practice. 
Regular attendance and input into the MDT meetings, adding to the clinical 
documentation, developing relevant clinical trials information resources and verbal 
communication helps build collaboration and encourages members of the MDT to refer 
all potentially eligible patients for consideration of recruitment into a clinical trials. The 
team are then aware when the patient goes onto participate and of their response to the 
study intervention. It also enables the team to consider and come to agreement about how 
the patients’ care will be managed once the trial has been completed.  
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 Continuum of care 
Whilst caring for a patient during their participation in a clinical trial it is inevitable that 
the nurse will recognise or be privy to patient or family needs or concerns, which may or 
may not be related to the symptom under investigation. The clinical trials nurse has a 
responsibility to refer to the MDT or other appropriate health professional to ensure the 
need is met. Examples include reporting an elevated temperature or blood sugar level to 
the team, or a more complex situation where the requirement for confidentiality requires 
the nurse to consider how to promote optimal care of the patient or family whilst ensuring 
ethical research practice. In the case study of Mrs M and her husband, the nurse became 
aware that Mr M was experiencing great distress about his wife’s condition when he 
consented to complete a caregiver quality of life questionnaire during Mrs M’s 
participation in the Octreotide study (Refer Table 5).  After acknowledging his distress 
and seeking his permission to share his responses with the team, the nurse ensured 
supportive interventions were initiated by appropriate team members.  
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Table 5: Case Study Mrs and Mr M 
Mrs M was referred to the Octreotide study, to which she consented and participated. Her 
husband Mr M consented to participate in the caregiver quality of life questionnaire. 
When the nurse read Mr M’s questionnaire, she noted that he reported high levels of 
stress, guilt, frustration and insomnia, and felt unsupported by his family. The clinical 
trials nurse spent time talking with Mr M about his responses and acknowledged what he 
was feeling. This discussion confirmed to the nurse that Mr M was experiencing a high 
level of distress. She asked for his permission to communicate this to the team so that 
more support could be provided. Mr M agreed, and the nurse then spoke with his 
consultant and documented her discussion with Mr M. The consultant then liaised with 
the social worker and bereavement counselor to provide more intensive support for Mr 
M. 
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 Systematic assessment 
Care of the patient may be enhanced through the use of validated assessment tools. For 
example, assessment tools for delirium are not currently routinely used in palliative care 
clinical practice, despite the prevalence, seriousness, under-recognition and distressing 
nature of delirium in this population (Lawlor et al 2000; Agar & Lawlor 2008; Bruera et 
al 2009). The ‘Risperidone for delirium’ study (Agar et al) uses the Memorial Delirium 
Assessment Scale (MDAS) (Breitbart et al 1997; Lawlor et al 2000) and the Nursing 
Delirium Screening Scale (NuDESC) (Gaudreau 2005) to assess both eligibility and 
response during the study intervention period. Several delirium evaluation instruments 
exist, however this study requires tools which allow repeated assessments and measured 
change in severity over time (Agar et al). The MDAS is a brief, valid and reliable tool for 
assessing delirium severity in advanced cancer patients, and was developed to be 
consistent with DSM IV criteria (Breitbart et al 1997; Lawlor et al 2000). The MDAS is 
performed at eligibility (eligibility requires a score of >7) and daily between 8 am and 12 
midday using information from the preceding 24 hour period. The Nu-DESC is a simple 
to use 5 item validated screening tool which enables continuous assessment of fluctuating 
delirium symptoms (Gaudreau 2005). A score of at least 1 in one of items 2 (altered 
communication), 3 (altered behaviour) or 4 (illusions/hallucinations) is required for a 
patient to be eligible; in addition it is the primary outcome measure of targeted delirium 
symptoms in the study. The NuDESC score is obtained at the end of each nursing shift by 
ward nursing staff, and also at 8am and 4pm by the clinical trials nurse, to determine the 
dose titration of the study medication. 
Both tools contribute to systematic assessment and documentation of the symptoms of 
delirium for patients being both screened and participating in the study. Appropriate 
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interventions such as modification or treatment of precipitating factors and reassurance 
and explanation to the patient and family are then facilitated by communication between 
the clinical trials nurse, the Site Investigator and the MDT. Systematic assessment is 
likely to contribute to better understanding of complex symptoms under investigation and 
the experience of individual patients at participating sites.  
Thus through optimal communication, assessment and promotion of care of participants 
clinical trials nurses achieve congruence with the philosophy of palliative care and 
integrate clinical trial activities into routine multidisciplinary care. 
Establishing and Building the Evidence Base   
Integration of clinical trial practice with multidisciplinary care also has the potential to 
influence care of patients who do not participate. There is some evidence that patients 
treated at hospitals participating in clinical trials have better outcomes than patients at 
hospitals which do not (Majumdar et al 2008). Majumdar et al hypothesised that clinical 
trial activity: 
“…has been developed to ensure that trial subjects receive safe, high-quality, 
protocol-driven care from highly trained research personnel overseen by 
experienced and well-informed investigators…these same elements could induce 
beneficial changes in the hospital environment, thereby leading to better processes 
and outcomes of care for patients treated outside the trial setting” (pp. 657- 658)  
Although this effect was demonstrated in the acute cardiac setting using the outcomes of 
in-hospital mortality and use of guideline-indicated care, there is potential for a similar 
effect within palliative care settings. It is not within the scope of this paper to show this 
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effect, however there are a number of processes undertaken by clinical trials nurses that 
are likely to implement and establish the evidence-base at participating sites, including:  
• Communicating the rationale for each clinical trial to the MDT 
• Highlighting evidence-practice gaps 
• Conducting audits on the local use of study medications when used “off-
study”  
• Integrating validated assessment tools into usual clinical practice  
• Contributing to review of local medication policies and protocols  
• Participation in journal clubs and research forums  
• Delivering education on research and evidence-based practice  
It is likely that these activities contribute to cultures which value questioning, reflective 
practice and evidence based practice, which has implications for all patients treated at the 
site (Janni et al 2006; Majumdar et al 2008). Working within the clinical trials role also 
develops participating nurses’ knowledge and skills in research and evidence-based 
practice. This professional development is likely to have implications in the volume and 
quality of these nurses’ future contribution to the generation of palliative care evidence.  
Conclusion 
The establishment of the PaCCSC clinical trials nurse role at across over a dozen 
Australian sites and completion of the first large RCT by the collaborative is testimony 
that recruiting palliative care patients to well designed RCT is feasible.  The contribution 
of the clinical trials nurse in facilitating successful implementation of these clinical trial 
protocols cannot be underestimated. Managing the consent process with often very 
unwell patients, integrating clinical trials into usual multidisciplinary care, and 
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establishing and building the evidence base at participating sites are all important aspects 
of the PaCCSC clinical trials nursing role. Clinical trials nurse roles have the potential to 
improve the research capacity of the palliative care sector and outcomes for patients 
requiring palliative care. There is also the potential to contribute to future intervention 
development and/or take the next step to become independent researchers. 
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